Edgen Stock·Sep 30 2025, 09:58戻る
戻る
Merck's WINREVAIR™ Demonstrates Significant Efficacy in Recently Diagnosed PAH Patients
Edgen Stock·Sep 30 2025, 09:58
[1] WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial[2] Merck & Co.'s Winrevair cuts progression by 76% in newly diagnosed PAH - Investing.com[3] WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial - Merck.com